Shares of health-care companies fell as traders bet the regulatory outlook would remain in limbo.
The Republican leadership is struggling to push a health-care overhaul bill that passed the House of Representatives through the Senate.
Continue Reading Below
Gilead's new "triple combo" AIDS/HIV treatment should help the biotech company keep its lead over a competing regimen, according to analysts at brokerage Leerink.
Rob Curran, email@example.com
(END) Dow Jones Newswires
May 30, 2017 17:23 ET (21:23 GMT)